The Iroquois homeobox proteins IRX3 and IRX5 have distinct roles in Wilms tumour development and human nephrogenesis.


Journal

The Journal of pathology
ISSN: 1096-9896
Titre abrégé: J Pathol
Pays: England
ID NLM: 0204634

Informations de publication

Date de publication:
01 2019
Historique:
received: 06 07 2018
revised: 27 08 2018
accepted: 16 09 2018
pubmed: 25 9 2018
medline: 20 12 2019
entrez: 25 9 2018
Statut: ppublish

Résumé

Wilms tumour is a paediatric malignancy with features of halted kidney development. Here, we demonstrate that the Iroquois homeobox genes IRX3 and IRX5 are essential for mammalian nephrogenesis and govern the differentiation of Wilms tumour. Knock-out Irx3

Identifiants

pubmed: 30246301
doi: 10.1002/path.5171
pmc: PMC6588170
doi:

Substances chimiques

Homeodomain Proteins 0
IRX3 protein, human 0
IRX5 protein, human 0
Irx3 protein, mouse 0
Irx5 protein, mouse 0
Transcription Factors 0
WNT5A protein, human 0
Wnt-5a Protein 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

86-98

Informations de copyright

© 2018 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of Pathological Society of Great Britain and Ireland.

Références

Nephron Exp Nephrol. 2014;128(1-2):80-8
pubmed: 25412793
Dev Cell. 2014 Apr 28;29(2):233-40
pubmed: 24726282
J Clin Pathol. 2010 Feb;63(2):102-9
pubmed: 19687012
Development. 2008 Oct;135(19):3197-207
pubmed: 18715948
Development. 2012 Nov;139(21):4007-19
pubmed: 22992950
Mech Dev. 2001 Sep;107(1-2):169-74
pubmed: 11520674
Dev Dyn. 2011 Aug;240(8):2011-27
pubmed: 21761484
Nat Methods. 2012 Jul 01;9(8):805-7
pubmed: 22751204
Trends Cell Biol. 2009 Mar;19(3):119-29
pubmed: 19208479
Oncol Rep. 2016 Jul;36(1):247-52
pubmed: 27222047
Br J Pharmacol. 2014 Mar;171(5):1195-209
pubmed: 24032637
Dev Cell. 2011 Feb 15;20(2):163-76
pubmed: 21316585
Mol Oncol. 2016 Nov;10(9):1415-1429
pubmed: 27522468
Organogenesis. 2011 Jul-Sep;7(3):180-90
pubmed: 22027435
Int J Cancer. 2003 Nov 10;107(3):365-74
pubmed: 14506735
Neoplasia. 2008 Dec;10(12):1470-80
pubmed: 19048125
Proc Natl Acad Sci U S A. 2011 Aug 16;108(33):13576-81
pubmed: 21825130
Cell Dev Biol. 2014 Jan 1;3(1):1000131
pubmed: 24855634
Nat Rev Genet. 2007 Oct;8(10):791-802
pubmed: 17878895
Development. 2014 May;141(10):2064-74
pubmed: 24764076
J Exp Clin Cancer Res. 2016 Sep 13;35(1):144
pubmed: 27623766
Nat Genet. 2012 May 13;44(6):709-13
pubmed: 22581230
J Am Soc Nephrol. 2017 Mar;28(3):852-861
pubmed: 27647853
Genes Chromosomes Cancer. 2014 May;53(5):381-91
pubmed: 24488803
Clin Cancer Res. 2008 Jun 1;14(11):3562-70
pubmed: 18519790
Int J Cancer. 2015 Mar 1;136(5):E252-61
pubmed: 25220031
PLoS One. 2017 Sep 8;12(9):e0184418
pubmed: 28886116
Am J Clin Pathol. 2014 Jun;141(6):828-33
pubmed: 24838327
Proc Natl Acad Sci U S A. 2012 May 15;109(20):E1267-76
pubmed: 22529373
Nat Cell Biol. 2013 Sep;15(9):1035-44
pubmed: 23974041
Mol Cell Biol. 2018 Apr 16;38(9):
pubmed: 29463648
Trends Cell Biol. 2013 Aug;23(8):380-9
pubmed: 23607968
Nat Genet. 2003 Jul;34(3):267-73
pubmed: 12808457
Mech Dev. 1997 Dec;69(1-2):169-81
pubmed: 9486539
Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50
pubmed: 16199517
Nat Rev Mol Cell Biol. 2010 Jun;11(6):404-13
pubmed: 20461097
Am J Physiol Renal Physiol. 2016 Aug 1;311(2):F241-8
pubmed: 27194720
Development. 2015 Aug 1;142(15):2564-73
pubmed: 26116661
Development. 2015 Aug 1;142(15):2574-85
pubmed: 26116666
Onco Targets Ther. 2016 Mar 11;9:1437-48
pubmed: 27042112
Cell. 2015 Aug 13;162(4):780-94
pubmed: 26276632
J Clin Oncol. 2005 Oct 10;23(29):7312-21
pubmed: 16129848
Exp Cell Res. 2010 Dec 10;316(20):3379-86
pubmed: 20643124
Genes Dev. 2007 Sep 15;21(18):2358-70
pubmed: 17875669
Curr Opin Genet Dev. 2002 Aug;12(4):403-8
pubmed: 12100884
Cell Rep. 2018 Jan 16;22(3):638-652
pubmed: 29346763
Pediatr Blood Cancer. 2014 Nov;61(11):1949-54
pubmed: 25044705
Am J Pathol. 2010 Nov;177(5):2609-21
pubmed: 20847289
Arch Dis Child. 2002 Sep;87(3):241-4
pubmed: 12193442
Science. 2013 Feb 15;339(6121):819-23
pubmed: 23287718
Pediatr Radiol. 2008 Jan;38(1):2-17
pubmed: 18026723
Pediatr Blood Cancer. 2010 Feb;54(2):316-8
pubmed: 19824073

Auteurs

Linda Holmquist Mengelbier (L)

Division of Clinical Genetics, Department of Laboratory Medicine, Lund University, Lund, Sweden.

Simon Lindell-Munther (S)

Division of Clinical Genetics, Department of Laboratory Medicine, Lund University, Lund, Sweden.

Hiroaki Yasui (H)

Division of Clinical Genetics, Department of Laboratory Medicine, Lund University, Lund, Sweden.
Department of Obstetrics and Gynecology, Graduate School of Medicine, Nagoya University, Nagoya, Japan.

Caroline Jansson (C)

Division of Clinical Genetics, Department of Laboratory Medicine, Lund University, Lund, Sweden.

Javanshir Esfandyari (J)

Division of Translational Cancer Research, Department of Laboratory Medicine, Lund University, Lund, Sweden.

Jenny Karlsson (J)

Division of Clinical Genetics, Department of Laboratory Medicine, Lund University, Lund, Sweden.

Kimberly Lau (K)

Program in Developmental and Stem Cell Biology, Research Institute, The Hospital for Sick Children, Toronto, ON, Canada.

Chi-Chung Hui (CC)

Program in Developmental and Stem Cell Biology, Research Institute, The Hospital for Sick Children, Toronto, ON, Canada.
Department of Molecular Genetics, University of Toronto, Toronto, ON, Canada.

Daniel Bexell (D)

Division of Translational Cancer Research, Department of Laboratory Medicine, Lund University, Lund, Sweden.

Sevan Hopyan (S)

Program in Developmental and Stem Cell Biology, Research Institute, The Hospital for Sick Children, Toronto, ON, Canada.
Department of Molecular Genetics, University of Toronto, Toronto, ON, Canada.

David Gisselsson (D)

Division of Clinical Genetics, Department of Laboratory Medicine, Lund University, Lund, Sweden.
Department of Pathology, Laboratory Medicine, Medical Services, University Hospital, Lund, Sweden.
Division of Oncology and Pathology, Department of Clinical Sciences, Lund University, Lund, Sweden.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH